X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.ema.europa.eu/en/documents/overview/ebvallo-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/ebvallo-epar-medicine-overview_en.pdf
https://www.pharmacompass.com/pdf/news/atara-biotherapeutics-ebvallo-tabelecleucel-receives-approval-in-europe-70175.pdf
https://www.ema.europa.eu/en/documents/overview/ebvallo-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/ebvallo-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/atara-makes-history-world-first-nod-allogeneic-t-cell-therapy-ebvallo
https://www.businesswire.com/news/home/20221218005055/en/Atara-Biotherapeutics%E2%80%99-Ebvallo%E2%84%A2-tabelecleucel-Receives-European-Commission-Approval-as-First-Ever-Therapy-for-Adults-and-Children-with-EBV-PTLD
https://endpts.com/chmp-offers-positive-opinion-for-two-high-profile-drugs-as-part-of-latest-batch-of-recommendations/
https://investors.atarabio.com/news-events/press-releases/detail/289/atara-biotherapeutics-to-receive-additional-near-term
https://endpts.com/ash-with-phiii-data-in-hand-atara-eyes-a-submission-to-treat-a-small-but-desperate-group-of-transplant-patients/
Market Place
Share 
